Home » Newsletters » BioWorld Science

BioWorld Science

June 28, 2018

View Archived Issues

Lundbeck initiates phase I study with Lu-AF-28996 for Parkinson's disease

Rigel announces the initiation of phase I trial of R-835

How targeted therapies are lost in translation

Increasing the specificity of kappa-opioid agonists

Dzuveo approved in Europe

FDA grants priority review for glasdegib in previously untreated acute myeloid leukemia

Vamorolone demonstrates improvements in strength and endurance in boys with DMD

First patient dosed in phase II study of REL-1017 in patients with major depressive disorder

FDA grants orphan drug designation for cannabidiol as treatment of autoimmune hepatitis

PharmaMar and Chugai announce early termination of the license agreement for Zepsyre in Japan

Preliminary data from phase Ib/II study of PCM-075 in combination with cytarabine or decitabine

Positive topline data presented from phase II/III study of CR-845

Results presented for KEYNOTE-046 study of ADXS-PSA plus pembrolizumab in patients with mCRPC

Aldeyra announces additional clinical programs planned for next year

Roivant creates new business units and launches Altavant Sciences

Part A data from phase III HOPE study of voxelotor in sickle cell disease show primary endpoint met

MSDC-5514 - a novel insulin sensitizer to treat diabetes and nonalcoholic steatohepatitis

FDA approves Braftovi + Mektovi for unresectable or metastatic melanoma

Omeros obtains approvals to begin phase I trial with PDE7 inhibitor OMS-527

Medivir reports promising topline results from phase IIa extension study of MIV-711

Gachon University, Seoul National University identify SIRT1 activators

Vertex patents CFTR modulators

FDA grants priority review to Jazz's pediatric sNDA for Xyrem

Microtubule-specific brain-penetrating PET imaging agent [11C]HD-800 characterized

ExCellThera completes phase I/II trial of ECT-001 technology in leukemia

Benefits seen with MEDI-0382 in overweight/obese subjects with type 2 diabetes

Alexion seeks E.U. approval for ALXN-1210 for PNH

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...